CompletedPhase 3NCT00161863
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Studying Encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Baxter BioScience InvestigatorBaxter BioScience
- Intervention
- FSME-IMMUN NEW 0.25 ml(biological)
- Eligibility
- 1-15 years · All sexes
- Timeline
- 2002 – 2003
Study locations (8)
- Grieskirchner Strasse 17, Wels, Austria
- Marktplatz 3, Bad Saulgau, Germany
- Solothurner Strasse 2, Heilbronn, Germany
- Hauptstraße 240, Kehl, Germany
- Wojewodzki Szpital Dziececy oddz. Obserwacyjno-Zakazny, Kielce, Poland
- Szpital Jana Pawla II Odz. Neuroinfekcji, Krakow, Poland
- Samodzielny Publiczny ZOZ Oddzial Dzieciecy, Lubartów, Poland
- PANTAMED sp.z.o.o., Olsztyn, Poland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00161863 on ClinicalTrials.govOther trials for Encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07511049Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot StudyNational Institute of Neurological Disorders and Stroke (NINDS)
- ACTIVE NOT RECRUITINGNCT07554261Clinical Features and Outcomes of VZV CNS InfectionsKocaeli University
- RECRUITINGNCT07332234Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesSpitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
- ACTIVE NOT RECRUITINGNCT06820060Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel PlusQIAGEN Gaithersburg, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineBavarian Nordic
- RECRUITINGPHASE1, PHASE2NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsSK Bioscience Co., Ltd.
- RECRUITINGNCT06368648CoMind Early Feasibility StudyCoMind Technologies Limited
- ACTIVE NOT RECRUITINGPHASE4NCT06678373Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasLiaoning Chengda Biotechnology CO., LTD